Cure My Disease

Don't miss your cure!

 Log in / Sign up

Schizophrenia protein may flag hidden heart risk

NCT ID NCT06304233

Knowledge-focused Sponsor: Norwegian University of Science and Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study investigates whether a protein called DISC1, known for its role in schizophrenia, is also linked to heart function in people with the condition. Researchers will measure DISC1 levels in blood and use heart imaging (echocardiograms, cardiac MRI, and ECGs) to assess heart structure and performance in 120 adults with schizophrenia. The goal is to see if DISC1 could serve as a biomarker for heart disease, which is more common in this population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If a link is found, it could point toward a new way to identify heart disease risk in people with schizophrenia, potentially leading to earlier monitoring or treatment.
What could go wrong
This is an observational study, not a treatment trial. It may find no clear connection, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Jun 2038

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The cohort with schizophrenia will be recruited from outpatient and inpatient population from a single centre. The cohort without mental health diagnosis will be selected from an existing population registered in the HUNT data and biobank and be matched for age (± 2 years) and sex of the patients.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with ICD-10 schizophrenia, schizotypal or delusional disorders (F20 to F29) * Both inpatient and outpatient * Capable of giving informed consent Exclusion Criteria: * Current or previous diagnosis of cancer * Current or previous treatment with chemotherapy * Current pregnancy * Mothers less than 6 months post-partum

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart diseases Heart; functional disturbance Schizophrenia

Contacts and locations

Locations

  • Norwegian University of Science and Technology

    Trondheim, Norway

  • St Olavs Hospital, Trondheim University Hospital

    Trondheim, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.